Interaction of the T cell receptor (TCR) with an MHC-antigenic peptide complex results in
changes at the molecular and cellular levels in T cells. The outside environmental cues are …

In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …

LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin
superfamily, is confirmed to be expressed on activated immune cells, mainly including …

Despite the impressive impact of CTLA 4 and PD 1‐PDL 1‐targeted cancer immunotherapy,
a large proportion of patients with many tumor types fail to respond. Consequently, the focus …

phenix. refine is a program within the PHENIX package that supports crystallographic
structure refinement against experimental data with a wide range of upper resolution limits …

The success of adoptive T cell gene transfer for treatment of cancer and HIV is predicated on
generating a response that is both durable and safe. We report long-term results from three …

Since the first crystal structure determinations of αβ T cell receptors (TCRs) bound to class I
MHC-peptide (pMHC) antigens in 1996, a sizable database of 24 class I and class II …

The immune checkpoint receptor lymphocyte activation gene 3 protein (LAG3) inhibits T cell
function upon binding to major histocompatibility complex class II (MHC class II) or …

The activation of T cells through interaction of their T-cell receptors with antigenic peptide
bound to major histocompatibility complex (MHC) on the surface of antigen presenting cells …

The interaction between the T‐cell receptor (TCR) and its peptide–major histocompatibility
complex (pepMHC) ligand plays a critical role in determining the activity and specificity of …